Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0P9MW
|
|||
Former ID |
DIB015231
|
|||
Drug Name |
IMP-321
|
|||
Synonyms |
Soluble CD223 (cancer), Immutep; Soluble LAG-3 (cancer), Immutep
Click to Show/Hide
|
|||
Indication | Allergy [ICD-11: 4A80-4A85; ICD-10: T78.4; ICD-9: 995.3] | Phase 1/2 | [1] | |
Company |
Immutep SA
|
|||
Structure |
Download2D MOL |
|||
Formula |
C56H78N18O14S
|
|||
Canonical SMILES |
C1=CC(=CC=C1CC(C(=O)NC(CCCCN)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN(C(=O)CNC(=O)CCC(=O)NCCC2=CN=CN2)C(=O)CNC(=O)CCC(=O)NCCC3=CN=CN3)C(=O)N)NC(=O)C4=CC=C(C=C4)NC(=S)NN)O
|
|||
InChI |
1S/C56H78N18O14S/c57-23-3-1-6-41(70-55(88)43(27-34-7-13-39(75)14-8-34)72-52(85)35-9-11-36(12-10-35)68-56(89)73-59)53(86)71-42(15-20-50(82)83)54(87)69-40(51(58)84)5-2-4-26-74(48(80)30-64-46(78)18-16-44(76)62-24-21-37-28-60-32-66-37)49(81)31-65-47(79)19-17-45(77)63-25-22-38-29-61-33-67-38/h7-14,28-29,32-33,40-43,75H,1-6,15-27,30-31,57,59H2,(H2,58,84)(H,60,66)(H,61,67)(H,62,76)(H,63,77)(H,64,78)(H,65,79)(H,69,87)(H,70,88)(H,71,86)(H,72,85)(H,82,83)(H2,68,73,89)/t40-,41-,42-,43-/m1/s1
|
|||
InChIKey |
ONKCBKDTKZIWHZ-MRWFHJSOSA-N
|
|||
CAS Number |
CAS 928150-91-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Lymphocyte activation gene 3 protein (LAG3) | Target Info | Immunomodulator | [2], [3] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01308294) Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients. U.S. National Institutes of Health. | |||
REF 2 | A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11. | |||
REF 3 | IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.